Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund holders during the fourth quarter of 2025. On February 20, the company announced that its shareholders had approved the proposed merger with Abbott Laboratories. The decision was made at a special meeting held that day. Under the terms of the merger agreement, Abbott Laboratories will acquire Exact Sciences for $105 per share in cash, a transaction valued at approximately $21 billion in ...

Lumos lifts operating cash flow on FebriDx momentum as 1H FY26 loss widens Proactive uses images sourced from Shutterstock Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported revenue of US$6.12 million for the six months to December 31, 2025 (1H FY26), down slightly from US$6.31 million a year earlier, as the company progressed multiple FebriDx commercial and regulatory milestones in the US. Product sales rose, led by FebriDx, with sale of goods increasing to US$1.68 million from US$0.84 mil ...

MDxHealth (NasdaqCM:MDXH) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker5Good day, welcome to the MDxHealth fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on a touchtone phone. To withdraw your question, please pre ...

Key Takeaways TEM reported 83% Q4 revenue growth, fueled by Diagnostics and Data segment strength. Tempus AI achieved positive adjusted EBITDA, though GAAP loss hit $54.2M on stock comp and charges. Illumina posted 5% revenue growth and margin gains, despite tariff-driven gross margin pressure. In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulato ...

Physician Interview Now AvailableKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https: ...

OraSure Technologies (NasdaqGS:OSUR) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsAndrew Cooper - DirectorCarrie Eglinton Manner - President and CEOJason Plagman - VP of Investor RelationsKenneth McGrath - CFOConference Call ParticipantsMatt Etoch - AnalystNone - AnalystOperatorToday, thank you for standing by. Welcome to the OraSure Technologies 2025 fourth quarter earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation ...

OraSure Technologies (NasdaqGS:OSUR) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsAndrew Cooper - DirectorCarrie Eglinton Manner - President and CEOJason Plagman - VP of Investor RelationsKenneth McGrath - CFOConference Call ParticipantsMatt Etoch - AnalystNone - AnalystOperatorToday, thank you for standing by. Welcome to the OraSure Technologies 2025 Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation ...

On February 17, 2026, Baker Bros. Advisors disclosed a purchase of 455,208 shares of GRAIL (NASDAQ:GRAL), an estimated $39.33 million trade based on quarterly average pricing. What happened According to a recent SEC filing dated February 17, 2026, Baker Bros. Advisors increased its position in GRAIL by 455,208 shares. The estimated transaction value, based on the average unadjusted closing price during the fourth quarter of 2025, was $39.33 million. The quarter-end value of the position rose by $82.09 mi ...

Core Viewpoint - Exact Sciences Corporation has received overwhelming approval from its stockholders for the acquisition by Abbott, indicating strong support for the merger [1] Company Summary - Exact Sciences Corporation is a leading provider of cancer screening and diagnostic tests [1] - The acquisition by Abbott was approved at a special meeting where more than 99% of the votes cast were in favor, representing approximately 67% of the total outstanding shares of Exact Sciences [1]

Company Overview - Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, which is a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression [3] Recent Developments - As of February 19, 2026, all prefunded warrants issued in the October 2025 private placement have been fully exercised, resulting in approximately 972,000 shares of common stock outstanding [1] - The company has cash exercisable warrants outstanding for approximately 1.5 million shares, with a cash exercise price of $7.00 or greater per share [1] Stock Information - Recent Schedule 13G filings by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, which may lead to discrepancies in reported beneficial ownership share amounts [2]